J&J’s cell therapy is now approved for an earlier line of treatment than a competing drug from Bristol Myers. Meanwhile, a look at Mount Sinai’s…
multiple myelomaBefore that decision, J&J's drug Carvykti and Bristol Myers's treatment Abecma were both only available to people who previously received at leastThey add more options to a growing arsenal of treatments that have helped improve outcomes for people with multiple myeloma. People with the diseaseThere's no doubt that the approvals will expand the reach of both treatments to thousands of eligible patients.
Carvykti's eligibility as a second-line treatment for multiple myeloma"should limit the use" of other similar cell therapies in the following lines of therapy, Shi said.– therapies that work by modifying white blood cells known as T-cells to attack cancer. J&J's drug has gradually gained ground over Abecma in the CAR-T market for multiple myeloma, even though it first entered the market a year later.
Both J&J and Bristol Myers have outlined plans to boost production of their respective drugs. I'll be watching to see how that part of the story plays out later this year, so stay tuned.On Monday, I visited part of the Mount Sinai Health System, which spans eight hospital campuses and a medical school, to learn about how it's using generative artificial intelligence.
Dr. Bruce Darrow, the health system's interim chief digital and information officer, said Mount Sinai is evaluating use cases across patient care, education and research. Within patient care, anything the health system can do to safely help clinicians and staff speed up decision making is important, he said.
"I think it's a wellness tool," Margolies said."I think it's making me much more relaxed. When I think a mammogram is normal, and the AI thinks it's normal, I'm more confident hitting that normal button."
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Bristol Myers Squibb to Lay Off Majority of Mirati Therapeutics WorkforceFollowing its acquisition of Mirati Therapeutics, Bristol Myers Squibb plans to lay off a majority of the San Diego company's workforce over the next year. The job cuts will affect 423 employees, with 176 based in San Diego, 76 remote workers in California, and 171 out-of-state remote workers.
Read more »
The Center for Healthy Minds and Healthy Minds InnovationsThe Center for Healthy Minds at the University of Wisconsin–Madison conducts rigorous scientific research to bring new insights to the world. The affiliated nonprofit Healthy Minds Innovations develops tools to take action on these insights.
Read more »
Healthy Returns: What's next in the legal fight over Medicare drug price negotiationsThe legal battle over Medicare drug price negotiations is so far looking favorable for the Biden administration. Meanwhile, CNBC is on the ground at HIMSS!
Read more »
Healthy Returns: The first drug for a common, deadly liver disease is hereDrugmakers are racing to catch up to Madrigal Pharmaceuticals, which has the first drug for NASH liver disease. Meanwhile, AI takes center stage at HIMSS.
Read more »
Healthy Returns: Weight loss, diabetes drug ad spending tops $1 billionDrugmakers spent big on ads for weight loss and diabetes drugs such as Wegovy and Ozempic. Meanwhile, the FDA approved the first AI diagnostic tool for sepsis.
Read more »
Parts of Bristol, Bucks County flooded after Delaware River spills over its banksChopper 6 was over Bristol, Bucks County on Thursday where cars and trucks could be seen in a flooded parking lot.
Read more »